Implementing a system-wide cancer prehabilitation programme: The journey of Greater Manchester's 'Prehab4cancer'.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
03 2021
Historique:
received: 19 04 2020
accepted: 22 04 2020
pubmed: 23 5 2020
medline: 10 8 2021
entrez: 23 5 2020
Statut: ppublish

Résumé

Patients undergoing major cancer interventions such as major surgical resection, chemotherapy, radiotherapy, and immunotherapy are prone to the adverse effects of their cancer, as well as to the side effects of the treatments designed to cure them. The Prehabilitation process supports cancer patients in preparing for the physiological challenges of their cancer treatments, whilst aiming to shorten recovery time, reduce peri-operative complications and improve compliance with non-surgical treatments. Prehabilitation will be most useful in older patients. Greater Manchester Integrated Care system is the first regional system in the UK to introduce delivery of system-wide, large scale physical activity supported multi-modal prehabilitation and recovery programme, Prehab4Cancer as a standard of care for cancer patients. It builds upon the successful implementation of Enhanced Recovery After Surgery + programme to improve surgical care in Greater Manchester. During this review we describe the journey to develop a system wide prehabilitation model for patients with cancer. Prehab4Cancer to date has focused on robust co-design, development, and implementation of an effective service model with attention paid to stakeholder engagement. This has led to receipt of high numbers of referrals from across Greater Manchester for the all the cancer groups involved. The successful implementation of the P4C pathway in GM presents a best practice model that might be adopted by other local and combined authority areas nationally.

Identifiants

pubmed: 32439265
pii: S0748-7983(20)30438-8
doi: 10.1016/j.ejso.2020.04.042
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

524-532

Informations de copyright

Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest There are no conflicts of interest for this article for any of the authors.

Auteurs

John Moore (J)

Consultant in Intensive Care and Anaesthesia, Manchester University Hospital NHS Foundation Trust, Clinical Director GM Cancer Prehab4Cancer, University of Manchester, Manchester Metropolitan University, UK. Electronic address: john.moore@mft.nhs.uk.

Zoe Merchant (Z)

Programme Lead GM Cancer Prehab4Cancer/Specialist Occupational Therapist, UK.

Kirsty Rowlinson (K)

GM Active Programme Manager Prehab4Cancer, UK.

Karen McEwan (K)

Primary Care Lead for GM Cancer Prehab4Cancer, UK.

Matthew Evison (M)

Consultant in Respiratory Medicine, Manchester University Hospital, UK.

Gemma Faulkner (G)

Consultant Colorectal Surgeon, Royal Bolton Hospital, UK.

Javed Sultan (J)

Consultant Upper GI Surgeon, Salford Royal Hospital, UK.

Jamie S McPhee (JS)

Manchester Metropolitan University, UK.

James Steele (J)

UK Active Research Institute and Solent University, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH